Evaluation of HCV Viremia Testing Approaches Among PWID in Georgia
NCT03594838 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1672
Last updated 2020-07-22
Summary
This study will evaluate two novel approaches to improve access to Hepatitis C virus (HCV) confirmatory viremia testing. Both approaches are "Harm reduction site-based (HRS)" because HCV viremia testing will be initiated and test results will be provided at the HRSs. These approaches will be compared to the current standard of care (control) in which anti-HCV-positive individuals must travel to a HCV treatment centre for HCV viremia testing. The investigators hypothesize that improving access to viremia testing improves linkage to care and reduces loss to follow-up among those who screen anti-HCV-positive.
Conditions
- Hepatitis C, Chronic
Interventions
- OTHER
-
HCV viremia testing approaches
Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
Sponsors & Collaborators
-
The National Center for Disease Control and Public Health
collaborator UNKNOWN -
Health Research Union
collaborator UNKNOWN -
Foundation for Innovative New Diagnostics, Switzerland
lead OTHER
Principal Investigators
-
Sonjelle Shilton · Find
-
Irma Khonelidze · National Centre for Disease Control, Georgia
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-05-21
- Primary Completion
- 2019-09-30
- Completion
- 2020-07-21
Countries
- Georgia
Study Locations
More Related Trials
-
A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C
NCT01659567 ·Status: COMPLETED
-
Hepatitis C Antiviral Resistance in African-Americans
NCT00038974 ·Status: COMPLETED ·Phase: PHASE3
-
Early Detection of HCV in Injection Drug Users
NCT06431945 ·Status: RECRUITING
-
Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy
NCT07098481 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania
NCT06159504 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
NCT00857311 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
NCT01058512 ·Status: COMPLETED ·Phase: PHASE2
-
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
NCT00308048 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility and Acceptability of HCV Treatment in Pregnancy
NCT06367465 ·Status: RECRUITING
-
Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)
NCT05016609 ·Status: RECRUITING ·Phase: PHASE4
-
Immune Response to Hepatitis C Virus
NCT00006301 ·Status: COMPLETED
-
Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
NCT02590068 ·Status: TERMINATED ·Phase: NA
-
HCV Treatment in a Low-threshold Clinic
NCT04063839 ·Status: UNKNOWN
-
Identification to Elimination in HCV-Infected Individuals
NCT03195205 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)
NCT00895882 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients
NCT01387958 ·Status: TERMINATED ·Phase: PHASE2
-
Qualification of Point-of-Care Assays for Management of HCV Patients
NCT02335320 ·Status: UNKNOWN
-
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
NCT00493805 ·Status: TERMINATED ·Phase: PHASE4
-
HCV Post-Exposure Prophylaxis for Health Care Workers
NCT03313414 ·Status: WITHDRAWN ·Phase: PHASE4
-
Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects
NCT00958152 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Therapy for Chronic Hepatitis C Infection
NCT01805882 ·Status: COMPLETED ·Phase: PHASE2
-
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
NCT00535847 ·Status: COMPLETED ·Phase: PHASE2
-
Innovate, Involve, Inspire
NCT06604182 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
NCT02333292 ·Status: COMPLETED
-
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
NCT02532907 ·Status: COMPLETED